157 related articles for article (PubMed ID: 3802085)
1. Significance of breast carcinoma-associated antigens as a monitor of tumor burden: characterization by monoclonal antibodies.
Salinas FA; Wee KH; Ceriani RL
Cancer Res; 1987 Feb; 47(3):907-13. PubMed ID: 3802085
[TBL] [Abstract][Full Text] [Related]
2. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
Bray KR; Koda JE; Gaur PK
Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
[TBL] [Abstract][Full Text] [Related]
3. Detection of a breast tissue-associated antigen by antiserum to Raji cell-bound circulating immune complexes of human breast cancer.
Koestler TP; Papsidero LD; Nemoto T; Chu TM
Cancer Res; 1981 Jul; 41(7):2900-7. PubMed ID: 7018673
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune complexes in breast and lung cancer, before and after chemotherapy.
García MS; Barañao RI; Fernández O; Bordenave H; Rumi LS
Allergol Immunopathol (Madr); 1987; 15(1):15-8. PubMed ID: 3604838
[TBL] [Abstract][Full Text] [Related]
5. Significance of circulating immune complexes in pulmonary tuberculosis.
Samuel AM; Ashtekar MD; Ganatra RD
Clin Exp Immunol; 1984 Nov; 58(2):317-24. PubMed ID: 6437714
[TBL] [Abstract][Full Text] [Related]
6. [Circulating immune complexes in the serum of tumor patients].
Alvarez R; García Gómez A; Subiza JL; Domínguez J; Bootello A; Coll J
Rev Esp Oncol; 1982; 29(4):727-34. PubMed ID: 6927370
[TBL] [Abstract][Full Text] [Related]
7. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
8. MAM-6 antigen, a new serum marker for breast cancer monitoring.
Hilkens J; Kroezen V; Bonfrer JM; De Jong-Bakker M; Bruning PF
Cancer Res; 1986 May; 46(5):2582-7. PubMed ID: 3697998
[TBL] [Abstract][Full Text] [Related]
9. Measurement of a monoclonal antibody-defined, melanoma-associated antigen in human sera: correlation of circulating antigen levels with tumor burden.
Morgan AC; Crane MM; Rossen RD
J Natl Cancer Inst; 1984 Feb; 72(2):243-9. PubMed ID: 6582312
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a new tumor associated antigen from mammary carcinoma cells by monoclonal antibodies.
Czuppon AB
Biochem Int; 1987 Aug; 15(2):359-72. PubMed ID: 3435529
[TBL] [Abstract][Full Text] [Related]
11. Circulating immune complexes (CIC) in Hodgkin's disease. I. Levels and two-dimensional analysis.
Nerurkar AV; Advani SH; Gothoskar BP
Neoplasma; 1989; 36(2):199-205. PubMed ID: 2716924
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility and monitoring of breast cancer by circulating immune complexes.
Dass TK; Aziz M; Rattan A; Tyagi SP
Indian J Pathol Microbiol; 1992 Oct; 35(4):298-307. PubMed ID: 1344219
[TBL] [Abstract][Full Text] [Related]
13. [Circulating immune complexes in breast cancer].
Abecassis J; Petit JC; Eber M; Klein T; Rodier D; Janser JC; Methlin G
Bull Cancer; 1985; 72(1):42-7. PubMed ID: 3872691
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique.
Ren J; Chen Z; Juan SJ; Yong XY; Pan BR; Fan DM
Cancer; 2000 Jan; 88(2):280-5. PubMed ID: 10640958
[TBL] [Abstract][Full Text] [Related]
15. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
16. Identification of material with paternal HLA antigen immunoreactivity from purported circulating immune complexes in patients with gestational trophoblastic neoplasia.
Lahey SJ; Steele G; Berkowitz R; Rodrick ML; Ross DS; Goldstein DP; Zamcheck N; Wilson RE; Deasy JM
J Natl Cancer Inst; 1984 May; 72(5):983-90. PubMed ID: 6325794
[TBL] [Abstract][Full Text] [Related]
17. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer.
Hebbar M; Révillion F; Louchez MM; Vilain MO; Fournier C; Bonneterre J; Peyrat JP
Clin Cancer Res; 1998 Feb; 4(2):373-80. PubMed ID: 9516925
[TBL] [Abstract][Full Text] [Related]
18. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
19. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
20. Detection of tumor-associated antigens in the sera of lung cancer patients by three monoclonal antibodies.
Hirota M; Fukushima K; Terasaki PI; Terashita GY; Galton J; Kawahara M
Cancer Res; 1985 Dec; 45(12 Pt 1):6453-6. PubMed ID: 2998602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
